TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12028323
Drug: Frovatriptan dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan dose of 2.5 mg
Study: 12028323
Drug: Frovatriptan doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan doses above 2.5 mg
Study: 12028323
Drug: Frovatriptan doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan doses of 10 mg and above
Study: 10726234
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg for 1 week
Study: 10726234
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg for 3 weeks
Study: 2220578
Drug: Bepridil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (300 to 500 mg/day)
Study: 2220578
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 to 300 mg/day)
Study: 19646174
Drug: Burnout intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Burnout intervention programme (details on dosage and duration not available)
Study: 17825695
Drug: Placebo (100-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100-mL saline)
Study: 17825695
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol 100 mg in 100-mL saline
Study: 2406858
Drug: Liquid bismuth
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid bismuth subsalicylate (BSS) 60 mL four times daily (4.2 g of BSS/d) for 3 weeks
Study: 2406858
Drug: BSS 2
Normalized name: BSS Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSS 2 tablets four times daily (2.1 g of BSS/d) for 3 weeks
Study: 2406858
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets taken four times daily) for 3 weeks
Study: 8032581
Drug: Dipyrone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 2.5 g
Study: 31536806
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE 0.625 mg/day) alone
Study: 28891251
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg q.d.
Study: 28891251
Drug: Baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2 mg q.d.
Study: 28891251
Drug: Baricitinib (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (twice-daily regimen)
Study: 26702941
Drug: Standard treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatments (group B)
Study: 24806137
Drug: Nefopam and
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam and Meperidine (both at 0.1 μg/mL)
Study: 27997725
Drug: Emollient cream
Normalized name: EMOLLIENT CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient cream (Dexeryl®) containing glycerol 15%, liquid and soft paraffin 10%, and other ingredients, applied twice daily for 27 ± 2 days
Study: 27585792
Drug: Cann‐CBD (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cann‐CBD (8 mg THC)
Study: 27585792
Drug: Cann +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cann + CBD (8 mg THC + 10 mg CBD)
Study: 27585792
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-dependent, drug-using)
Study: 25158709
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injections into the orbicularis oris muscle
Study: 25158709
Drug: Vehicle injections
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle injections into the orbicularis oris muscle
Study: 22178274
Drug: Two-needle technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-needle technique for TMJ arthrocentesis plus hyaluronic acid injections
Study: 16635050
Drug: Active analgesics
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active analgesics
Study: 15579788
Drug: Low-dose T3
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose T3 (25 microg) with paroxetine 30 mg daily
Study: 15579788
Drug: High-dose T3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose T3 (25 microg twice daily) with paroxetine 30 mg daily
Study: 15579788
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with paroxetine 30 mg daily
Study: 12959313
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg day(‐1))
Study: 2825462
Drug: atracurium 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.02 mg/kg
Study: 2825462
Drug: atracurium 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.03 mg/kg
Study: 2825462
Drug: atracurium 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.04 mg/kg
Study: 9424681
Drug: atracurium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.05 mg/kg
Study: 18447946
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with a proton pump inhibitor
Study: 7847434
Drug: TMP/SMX thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMX thrice weekly (3 times per week)
Study: 7847434
Drug: TMP/SMX daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMX daily (twice daily)
Study: 1826822
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of abrasio and high-dose gestagen treatment
Study: 31171928
Drug: Domperidone treatment
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone treatment for 14 days
Study: 24163093
Drug: Continuous intraarticular
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraarticular infusion of 0.2% ropivacaine
Study: 23136289
Drug: Community managed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community managed cases (excluding cost of antibiotics)
Study: 23136289
Drug: Referred cases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referred cases (excluding cost of antibiotics)
Study: 11175678
Drug: Timed 'Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed 'Up & Go' test (TUG) during 'on' phase of levodopa (1 hour after administration)
Study: 2878457
Drug: 0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/kg ethanol (control)
Study: 7949539
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (FeDs, n = 12)
Study: 3357722
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy and behavior change
Study: 21873922
Drug: Office-based vergence/accommodative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based vergence/accommodative therapy with home reinforcement (OBVAT)
Study: 19668097
Drug: Home-based computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+)
Study: 18852411
Drug: Office-based placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based placebo therapy with home reinforcement (OBPT)
Study: 18284711
Drug: CoQ10 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (300 mg per day for 20 days)
Study: 18284711
Drug: Placebo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (300 mg per day for 20 days)
Study: 12220476
Drug: Urinary LTE4
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary LTE4 excretion
Study: 10574416
Drug: Benidipine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine treatment
Study: 1767175
Drug: Troxerutine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troxerutine (4 g/day)
Study: 6123277
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine orally at 2200 hours on the evening before surgery and a further 150 mg 1-2 hours before operation (Group A)
Study: 6123277
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine with premedication only (Group B)
Study: 19329822
Drug: rosuvastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin, 20 mg per day
Study: 14704596
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (niacin, bile acid sequestrant, ezetimibe)
Study: 9825271
Drug: Ibuprofen-arginine (IA)
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen-arginine (IA) 400 mg
Study: 3081148
Drug: Conventional combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional combined test using insulin together with thyrotrophin releasing hormone and luteinising hormone releasing hormone
Study: 18955431
Drug: Weekly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly phone call (control group)
Study: 11264333
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus 16 sessions of manualized group psychotherapy
Study: 11264333
Drug: Continued medication
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medication only (fluoxetine)
Study: 9497790
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin infusion (28.9 +/- 2.1 mu-units/ml)
Study: 9497790
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin infusion (101.7 +/- 6.8 mu-units/ml)
Study: 3092712
Drug: Auranofin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (6 mg/d)
Study: 3092712
Drug: D-penicillamine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (250 mg/d for 4 weeks, 500 mg/d for 4 weeks, then 750 mg/d thereafter)
Study: 12126343
Drug: Standard pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacotherapy alone
Study: 27404027
Drug: Ospemifene 60
Normalized name: ospemifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ospemifene 60 mg/d
Study: 24178236
Drug: Mirabegron OCAS
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron OCAS 25-400 mg single doses
Study: 24178236
Drug: Mirabegron OCAS
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron OCAS up to 400 mg single doses
Study: 24178236
Drug: Mirabegron OCAS
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron OCAS up to 200 mg multiple doses
Study: 17618766
Drug: Posterior colporrhaphy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior colporrhaphy, site-specific repair, site-specific repair with Fortagen graft augmentation (specific intervention details not provided)
Study: 11805614
Drug: Sygen (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sygen (two doses)
Study: 9543170
Drug: Hydrocortisone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (25 mg as an i.v. bolus)
Study: 17056948
Drug: ondansetron, droperidol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron, droperidol, or their combination
Study: 7028532
Drug: Maprotiline (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (reference drug)
Study: 26049702
Drug: Molecular imaging
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular imaging as a biomarker for targeted cancer therapy
Study: 9271481
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (up to 1.25 mg of conjugated equine estrogens daily, along with 5 mg of medroxyprogesterone acetate daily)
Study: 9241623
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg daily)
Study: 8511810
Drug: Chloroquine-Proguanil combination
Normalized name: chloroquine / proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine-Proguanil combination (CQ+PROG)
Study: 20692561
Drug: Besifloxacin 0.6%
Normalized name: BESIFLOXACIN 0.6% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifloxacin 0.6% ophthalmic suspension
Study: 8450081
Drug: Metronidazole 200
Normalized name: metronidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 200 mg x 3 x 10 days
Study: 8450081
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg x 4 x 12 days
Study: 3096763
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate 100 mg daily for four weeks
Study: 2974306
Drug: Acitretin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (10 mg capsules, 3 capsules/day for 4 weeks, followed by varying doses for 8 weeks)
Study: 2974306
Drug: Etretinate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (10 mg capsules, 3 capsules/day for 4 weeks, followed by varying doses for 8 weeks)
Study: 28941589
Drug: Dexamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (12 mg intravenous before chemoembolization)
Study: 20037525
Drug: Rectal suppository
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppository (50 mg)
Study: 20037525
Drug: Tablet (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (50 mg)
Study: 16390864
Drug: GH +
Normalized name: Delsym Cough + Cold Daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH + sex steroids
Study: 15214586
Drug: tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibolone 1.25 mg/day
Study: 3536489
Drug: Cyclizine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine, 50 mg
Study: 3536489
Drug: Perphenazine, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine, 2.5 mg
Study: 28185407
Drug: Dialysate temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate temperature at 37°C and sodium concentration at 138 mmol/L (Mode A)
Study: 28185407
Drug: Dialysate temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate temperature at 35°C and sodium concentration at 138 mmol/L (Mode B)
Study: 25049330
Drug: Sequential sunitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential sunitinib then everolimus
Study: 19651171
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg non-adjuvanted RSV-A vaccine
Study: 19651171
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg adjuvanted RSV-A vaccine
Study: 9854507
Drug: Endogenous/exogenous TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endogenous/exogenous TNF therapy (EET) with recombinant TNF‐SAM2 (rTNF‐S) and anti-cancer drugs (mitomycin-C and 5-FU)
Study: 9854507
Drug: Endogenous/exogenous TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endogenous/exogenous TNF therapy (EET) alone
Study: 2361813
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg daily)
Study: 2191749
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of prophylactic antibiotics
Study: 2191749
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of prophylactic antibiotics
Study: 31618430
Drug: Zinc (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (25 mg) supplementation
Study: 26096777
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% and benzoyl peroxide 2.5% gel (A-BPO)
Study: 15088723
Drug: FM 2/Diafix‐oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM 2/Diafix‐oral
Study: 15088723
Drug: FM 2/MPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM 2/MPS gel (ceramic)
Study: 9543160
Drug: Subcutaneous abdominal
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous abdominal fat area
Study: 25260214
Drug: Present Centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present Centered Therapy (PCT)
Study: 29183930
Drug: Chlorhexidine (0.1%)
Normalized name: chlorhexidine 0.01 MG/MG
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (0.1%) solution for meatal cleaning prior to catheter insertion
Study: 25439116
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with adjunct intervention (guided imagery/relaxation exercises DVD)
Study: 23224788
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg aprepitant
Study: 21332630
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg)
Study: 16988169
Drug: Valdecoxib, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib, 40 mg with a 20-mg redose (n = 127)
Study: 16988169
Drug: Valdecoxib, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib, 40 mg with a placebo redose (n = 122)
Study: 16988169
Drug: Valdecoxib, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib, 20 mg twice daily (n = 160)
Study: 16988169
Drug: Valdecoxib, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib, 20 mg once daily (n = 159)
Study: 2568838
Drug: bopindolol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol (0.05 mg, 0.5 mg, 1 mg, 2 mg)
Study: 2568838
Drug: nifedipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (2 x 20 mg)
Study: 27234199
Drug: PTSD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTSD treatment participation
Study: 27407018
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for 6 months
Study: 16648506
Drug: Oral uracil
Normalized name: uracil
DrugBank: Uracil (DB03419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral uracil and tegafur (UFT) plus leucovorin (LV)
Study: 15612616
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of fluconazole 200 mg
Study: 6195795
Drug: Local chemotherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local chemotherapy (doxorubicin) for carcinoma in situ
Study: 6195795
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy after complete transurethral resection of superficial bladder tumors
Study: 6195795
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy following radical surgery or radiotherapy
Study: 27874971
Drug: Cefiderocol 1000
Normalized name: cefiderocol 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefiderocol 1000 mg intravenous infusion
Study: 18158690
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of vitamin E
Study: 18158690
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of vitamin C
Study: 18158690
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of vitamin E and 1000 mg of vitamin C
Study: 14693597
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg/kg followed by cisatracurium 0.03 mg/kg
Study: 14693597
Drug: cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisatracurium 0.15 mg/kg followed by cisatracurium 0.03 mg/kg
Study: 14693597
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg/kg followed by rocuronium 0.15 mg/kg
Study: 11858491
Drug: Ximelagatran (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (60 mg p.o.)
Study: 2193712
Drug: Inderal LA
Normalized name: Inderal LA
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inderal LA 160 mg daily
Study: 2193712
Drug: Half-Inderal LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-Inderal LA 80 mg daily
Study: 16788808
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN)
Study: 19689921
Drug: Modafinil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (up to 300 mg/d)
Study: 15502050
Drug: PTX 5
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX 5 mg/kg IV infusion before anesthesia induction
Study: 28987470
Drug: ω‐3 long
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 long chain‐PUFA (2.9 g/day)
Study: 25693783
Drug: Ixekizumab 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 25 mg
Study: 25693783
Drug: Ixekizumab 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 75 mg
Study: 25693783
Drug: Ixekizumab 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 150 mg
Study: 19077131
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or venlafaxine (n = 30)
Study: 9440743
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant external-beam radiation therapy (XRT)
Study: 8206471
Drug: Empiric self-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric self-treatment with clotrimazole 500 mg ovule at the onset of symptoms for 6 months
Study: 2914540
Drug: Sennosides (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sennosides (30 mg orally at 7:00 PM)
Study: 4736626
Drug: Stilboestrol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stilboestrol 7.5 mg daily
Study: 4736626
Drug: Stilboestrol 15
Normalized name: Stilboestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stilboestrol 15 mg daily